Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 40 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| CRISPR Therapeutics AG | CRSP | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 55.56 | 04:04:55 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 55.56 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 8 | 40 | - | 37.55 - 91.10 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 04:16:39 | 5 | $ 55.75 | USD |
CRISPR Therapeutics (CRSP) Options Flow Summary
CRISPR Therapeutics AG Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 4.46B | 80.28M | - | 371.21M | -153.61M | -1.91 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
CRISPR Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CRSP Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 62.70 | 63.08 | 55.52 | 58.90 | 1,234,742 | -7.14 | -11.39% |
| 1 Month | 73.78 | 75.91 | 55.52 | 64.92 | 1,260,482 | -18.22 | -24.70% |
| 3 Months | 62.87 | 91.10 | 55.52 | 74.08 | 1,769,007 | -7.31 | -11.63% |
| 6 Months | 43.43 | 91.10 | 37.55 | 65.30 | 2,359,611 | 12.13 | 27.93% |
| 1 Year | 54.79 | 91.10 | 37.55 | 61.90 | 1,738,819 | 0.77 | 1.41% |
| 3 Years | 117.12 | 169.67 | 37.55 | 71.75 | 1,505,472 | -61.56 | -52.56% |
| 5 Years | 36.73 | 220.21 | 32.00 | 80.15 | 1,343,400 | 18.83 | 51.27% |
CRISPR Therapeutics Description
| CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes. |
